PRINCETON, NJ--Bristol-Myers Squibb Company has received FDA clearance to market Etopophos (etoposide phosphate) for injection, a new water-soluble version of its anticancer drug VePesid (etoposide).
Etopophos can be administered in as few as 5 minutes, representing a marked advantage over the 30- to 60-minute infusion time required for VePesid, the company said.
Etopophos can also be given to patients in higher concentrations than VePesid, reducing by up to 1/50th the fluid volume infused.
The new version of the drug has the same indication as VePesid: to be used in combination with other approved chemotherapy agents as first-line treatment in patients with small-cell lung cancer and in combination with other approved chemotherapy agents in patients with refractory testicular tumors who have already received appropriate surgery, chemotherapy, and radiotherapy.
"This new version of etoposide(Drug information on etoposide) offers greater convenience to both patients and the medical professionals who care for them," said Michelle Daniels, MD, director, Medical Information, Bristol-Myers Squibb Oncology. "Patients may now spend a lot less time in the clinic receiving their treatment."